Akston Biosciences, which develops new classes of biologic therapeutics, and LakePharma, a U.S.-based CRDMO serving the biotechnology community with development and production services, have established a strategic partnership.   LakePharma will manufacture commercial quantities of Akston’s adjuvated COVID-19 vaccine candidate (AKS-452), which is scheduled to begin Phase 1/2 clinical testing later this month.    About AKS-452   AKS-452 is an advanced COVID-19-specific Fc fusion protein vaccine i...